Pharmacokinetics and dosing regimens of direct oral anticoagulants in morbidly obese patients: an updated literature review
Y Zhao, M Guo, D Li, W Xu, C Pan… - Clinical and Applied …, 2023 - journals.sagepub.com
Data on the impact of morbid obesity (body mass index [BMI]≥ 40 kg/m2) on the
pharmacokinetics (PK), pharmacodynamics (PD) of direct oral anticoagulants (DOACs) are …
pharmacokinetics (PK), pharmacodynamics (PD) of direct oral anticoagulants (DOACs) are …
Use of direct oral anticoagulants in morbidly obese patients
K Kido, JC Lee, T Hellwig… - … : The Journal of Human …, 2020 - Wiley Online Library
In 2016, the International Society on Thrombosis and Haemostasis (ISTH) published
guidelines advising caution when using direct oral anticoagulants (DOACs) in patients with …
guidelines advising caution when using direct oral anticoagulants (DOACs) in patients with …
Evaluation of the efficacy of direct oral anticoagulants (DOACs) in comparison to warfarin in morbidly obese patients
C Kalani, E Awudi, T Alexander, G Udeani… - Hospital …, 2019 - Taylor & Francis
Purpose: There is limited clinical data evaluating anticoagulation with the direct oral
anticoagulants (DOACs) in morbidly obese patients. We sought to examine the efficacy in …
anticoagulants (DOACs) in morbidly obese patients. We sought to examine the efficacy in …
[HTML][HTML] Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH
K Martin, J Beyer‐Westendorf, BL Davidson… - Journal of Thrombosis …, 2016 - Elsevier
Four direct‐acting oral anticoagulants (DOACs)–the thrombin inhibitor dabigatran, and the
activated factor X (FXa) inhibitors apixaban, edoxaban, and rivaroxaban–are approved in …
activated factor X (FXa) inhibitors apixaban, edoxaban, and rivaroxaban–are approved in …
A single center retrospective cohort study evaluating use of direct oral anticoagulants (DOACs) in morbidly obese veteran population
T Patil, M Lebrecht - Thrombosis research, 2020 - Elsevier
Abstract Background Direct oral anticoagulants (DOACs) are preferred over warfarin for the
treatment of venous thromboembolism (VTE) as well as atrial fibrillation (AF). The efficacy …
treatment of venous thromboembolism (VTE) as well as atrial fibrillation (AF). The efficacy …
Efficacy and safety of direct‐acting Oral anticoagulants (DOACs) in the overweight and obese
Obesity plays an essential role in the safety of pharmacologic drugs. There is paucity of data
for direct oral anticoagulants (DOACs) in the obese, despite these agents becoming more …
for direct oral anticoagulants (DOACs) in the obese, despite these agents becoming more …
Direct oral anticoagulants in obesity: an updated literature review
J Sebaaly, D Kelley - Annals of Pharmacotherapy, 2020 - journals.sagepub.com
Objective: To review literature on the use of direct-acting oral anticoagulants (DOACs) in
patients with high body weight (BW) and/or high body mass index (BMI) and to make …
patients with high body weight (BW) and/or high body mass index (BMI) and to make …
Direct-Acting Oral Anticoagulants in patients at extremes of body weight: a review of pharmacological considerations and clinical implications
Patients at extremes of body weight are underrepresented in randomized controlled trials of
direct-acting oral anticoagulants (DOACs). Therefore, their optimal anticoagulant treatment …
direct-acting oral anticoagulants (DOACs). Therefore, their optimal anticoagulant treatment …
[HTML][HTML] Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: a retrospective study
Background Due to a paucity of data on the efficacy and safety of direct oral anticoagulants
(DOACs) in patients with a body mass index> 40 kg/m 2 or a weight> 120 kg, the use of …
(DOACs) in patients with a body mass index> 40 kg/m 2 or a weight> 120 kg, the use of …
Efficacy and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients (BMI ≥ 30 kg/m2) with Atrial Fibrillation or Venous Thromboembolism: An …
P Karakasis, N Ktenopoulos, K Pamporis… - Journal of Clinical …, 2024 - mdpi.com
Background: Real-world data show limited utilization of direct oral anticoagulants (DOACs)
in obese patients (body mass index [BMI]≥ 30 kg/m2) due to concerns regarding their …
in obese patients (body mass index [BMI]≥ 30 kg/m2) due to concerns regarding their …